Bruland Home
List of publications
Scientific projects
Selected papers
Curriculum vitae
Latest news
Alpharadin
Osteosarcoma
In the media
Collaboration
Web links
Lectures
Symposia
Cultural projects
Various activites
Clips & photos
Vintage fishing tackle
File exchange

 

 
Professor Øyvind S. Bruland
 

Professor Øyvind S. Bruland

 
 

Alpharadin og prostatakreft med spredning til skjelett

Alpharadin and prostate cancer with skeletal metastases

Bone scintigPrimitive bone matrix (“target for Alpharadin”) produced and present throughout the entire metastasis – Spiral CT-image; A coronal section
The nature of sclerotic/osteoblastic bone metastases and the microdistribution of primitive bone matrix; i.e. the target for Radium-223 (Alpharadin), is a prerequisite for the therapeutic effect.

Click here to view three slides visualizing this dimension.

A mesh of new bone matrix entwined in between cords of tumor cells

 
 

Prostatakreft med spredning til skjelett


Radium-223 (Alpharadin) er i fase-3 klinisk utprøving hos pasienter med hormonresistent prostatakreft og symptomer fra spredning til skjelettet.

Her finner du, som pdf-dokument (klikk her), det foredraget jeg holdt under PROFO - Oslo & Akershus, "Prostatakreftforeningen", sitt årsmøte i Oslo 4/3-09.

For ytterligere informasjon om PROFO, se deres webside: www.prostatakreft.no

Algeta heter det norske firma som står bak utprøvingen, og på deres webside www.algeta.com finnes det detaljert informasjon om denne fase-3 studien under menyknappen "Alsympca" i venstre kolonne.

 
 

Alpharadin and Skeletal Metastases - A Phase III Trial

A direct link to the ongoing phase III trial, that recently was activated in US centers, directs you to the NIH/NCI clinical trials web page - click here.


Review of the clinical development of Radium 223 - Alpharadin.

Chapter 10 in a recent textbook on targeted radionuclide tumour therapy by Springer Verlag, 2008.

Click here to open the chapter in PDF format.

 
 

Prostate cancer with skeletal metastases.

This presentation, made by Algeta ASA (see www.algeta.com), presents important aspects on the efficacy and safety of Alpharadin.

Also it provides an introduction to put this novel bone-seeking targeted therapy based on alpha-paticle emitting Radium-223 in a comparative context; i.e. to the two other radiopharmaceuticels approved to releive pain and to the cytostatic drug Taxotere.

Click here for a pdf of the presentation

 
>> Print this page  [1700 visits]